OSRH_OUT_1 [2025-03-26 07:53:36 -0400] 1272 Bytes | 351 tokens | Cum: 351 tkns (4.39% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 7:53:35 AM on Wed Mar 26, 2025 -0400, and I'm firing up the spotlight on OSR (OSRH), moving from 1.6 to 3.49. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

Here's the first list of news for OSR:

C1 - Today 07:16AM - Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
C2 - Mar-25-25 07:00AM - OSR Holdings Appoints Dr. Constance Hfer as Chief Scientific Officer

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on OSR (OSRH)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

OSRH_OUT_3 [2025-03-26 07:53:40 -0400] 1043 Bytes | 291 tokens | Cum: 644 tkns (8.05% of 8k)
==========================================================================

Showing C1 (chunk 1 of 6): C1:
**Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma**
Date: Today 07:16AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/vaximm-ag-an-osr-company-announces-results-from-phase-2a-trial-of-vxm01-and-avelumab-combination-therapy-in-glioblastoma-302411928.html

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01

BASEL, Switzerland,March 26, 2025/PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VE

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

OSRH_OUT_5 [2025-03-26 07:53:42 -0400] 983 Bytes | 300 tokens | Cum: 1030 tkns (12.88% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-26T11:48:45Z - Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination T...
A2 - 2025-03-26T11:44:04Z - Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination T...
A3 - 2025-03-25T11:57:32Z - OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer | Taiwan News | Mar. 25, 2025 ...
A4 - 2025-03-25T11:20:07Z - OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer...
A5 - 2025-03-25T11:03:41Z - OSR Holdings (OSRH) Appoints Constance Höfer as Chief Scientific Officer...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

OSRH_OUT_7 [2025-03-26 07:53:44 -0400] 1038 Bytes | 294 tokens | Cum: 1326 tkns (16.57% of 8k)
==========================================================================

Showing A1 (chunk 1 of 8): A1:
**Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma | Taiwan News | Mar. 26, 2025 19:16**Date: 2025-03-26Source: {'uri': 'taiwannews.com.tw', 'dataType': 'news', 'title': 'Taiwan News'}URL: https://taiwannews.com.tw/en/news/6069493Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01

BASEL, Switzerland, March 26, 2025 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (P

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

OSRH_OUT_9 [2025-03-26 07:53:45 -0400] 1038 Bytes | 257 tokens | Cum: 1585 tkns (19.81% of 8k)
==========================================================================

Showing A1 (chunk 2 of 8): D-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.

Key results and observations:

The VXM01-avelumab combination therapy was generally well-tolerated, with the majority of safety events being mild to moderate in severity. These safety and tolerability data are in-line with previously reported data on avelumab alone with no additional safety signals for the combination of VXM01 and avelumab. No serious adverse events (SAEs) were attributed to VXM01, while 9 of 11 (81.8%) were related to the target disease, underscoring the well manageable safety profile of this combination therapy in a frail patient population. The non-resected patient cohort showed a 12.0% objective response rate (ORR). 12.0% of these patients showed a partial remission and 4.0% had stable disease. This suggests that, with further inv

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

OSRH_OUT_11 [2025-03-26 07:53:47 -0400] 267 Bytes | 67 tokens | Cum: 1654 tkns (20.67% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OSRH_OUT_13 [2025-03-26 07:53:48 -0400] 830 Bytes | 213 tokens | Cum: 1869 tkns (23.36% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-27 8-K Item1.01. Entry into a Material Definitive Agrmt.

Common Stock Purchase Agrmt

On February 25, 2025, OSR Holdings, Inc. (the Company) entered into a common stock purchase agreement (the Common Stock Purchase Agrmt) and a related registration rights agreement (the Wh...

S2 - 2025-02-21 8-K Item 1.01. Entry into a Material Definitive Agrmt.

Participating Joinders

Prior to the Closing Date, the Company entered into participating joinders (the Participating Joinders ) with the Participating Stockholders, pursuant to which the Company issued an aggregate of 16,...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OSRH_OUT_15 [2025-03-26 07:53:49 -0400] 1038 Bytes | 237 tokens | Cum: 2108 tkns (26.35% of 8k)
==========================================================================

Showing S1 (chunk 1 of 5): S1:
Item1.01. Entry into a Material Definitive Agreement.

Common Stock Purchase Agreement

On February 25, 2025, OSR Holdings, Inc. (the Company) entered into a common stock purchase agreement (the Common Stock Purchase Agreement) and a related registration rights agreement (the White Lion RRA) with White Lion GBM Innovation Fund (White Lion). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Common Stock Purchase Agreement.

Pursuant to the Common Stock Purchase Agreement, following its closing and following the effective date of a resale registration statement registering the shares issuable to White Lion in accordance with the terms of the White Lion RRA, the Company has the right, but not the obligation, to require White Lion to purchase, from time to time, up to the lesser of (i) $80,000,000 in aggregate gross purchase price of new

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

OSRH_OUT_17 [2025-03-26 07:53:51 -0400] 1038 Bytes | 241 tokens | Cum: 2351 tkns (29.39% of 8k)
==========================================================================

Showing S1 (chunk 2 of 5): ly issued shares of the Companys common stock, par value $0.0001 per share (the Common Stock), and (ii) the Exchange Cap, in each case, subject to certain limitations and conditions set forth in the Common Stock Purchase Agreement.

The number of shares of Common Stock that the Company may require White Lion to purchase in any single sales notice will depend on a number of factors, including the type of purchase notice that the Company delivers to White Lion. For example: (1) if the Company were to deliver a Rapid Purchase Notice, the Company can require White Lion to purchase a number of shares equal to $2,000,000 divided by the average of the three (3) lowest traded prices of the Common Stock on the Rapid Purchase Notice Date; and (2) if the Company were to deliver a VWAP Purchase Notice, the Company can require White Lion to purchase a number of shares equal to $2,000,000 divided by t

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

OSRH_OUT_19 [2025-03-26 07:53:59 -0400] 1038 Bytes | 239 tokens | Cum: 2592 tkns (32.40% of 8k)
==========================================================================

Showing S1 (chunk 3 of 5): he product of (i) the lowest daily VWAP of the Common Stock during the VWAP Purchase Valuation Period and (ii) ninety-seven percent (97%).

White Lions purchase obligations under a single Rapid Purchase Notice or a single VWAP Purchase Notice shall not exceed $2,000,000, and the maximum amount of shares of Common Stock the Company may require White Lion to purchase under a single VWAP Purchase Notice shall be the lesser of (A) 30% of the Average Daily Trading Volume or (B) $2,000,000 divided by the highest closing price of the Common Stock over the most recent five (5) Business Days immediately preceding White Lions receipt of the subject VWAP Purchase Notice.

The Common Stock Purchase Agreement will terminate automatically on the earlier of (i) December 31, 2026 and (ii) the date when the Company files for bankruptcy, has a bankruptcy case filed against it, has a custodian appointed fo

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

OSRH_OUT_21 [2025-03-26 07:54:16 -0400] 4406 Bytes | 1081 tokens | Cum: 3834 tkns (47.93% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+---------------------+------------------------+----------------------+-------------------+
| Volume: 55,652 | SMA50: -74.58% | Market Cap: 6.46M | Option/Short: No / Yes | Sales past 5Y: 0.00% | Sales Surprise: - |
+-------------------+-----------------------+---------------------+------------------------+----------------------+-------------------+
| Avg Volume: 1.55M | SMA200: -83.45% | Shs Outstand: 4.04M | Short Float: - | Employees: 2 | EPS Surprise: - |
+-------------------+-----------------------+---------------------+------------------------+----------------------+-------------------+
| Rel Volume: 0.03 | Perf Week: -10.61% | Shs Float: - | Short Ratio: 0.06 | Debt/Eq: 0.12 | P/E: - |
+-------------------+-----------------------+---------------------+------------------------+----------------------+-------------------+
| RSI (14): 30.69 | Perf Month: -53.08% | Inst Own: 0.35% | Short Interest: 0.09M | Sales Y/Y TTM: - | Earnings: - |
+-------------------+-----------------------+---------------------+------------------------+----------------------+-------------------+
| ATR (14): 0.60 | Perf Quarter: -86.29% | Insider Own: - | Beta: 1.40 | ROE: -1.13% | |
+-------------------+-----------------------+---------------------+------------------------+----------------------+-------------------+
| SMA20: -22.17% | Index: - | Insider Trans: - | Sales Q/Q: - | ROI: -3.18% | |
+-------------------+-----------------------+---------------------+------------------------+----------------------+-------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

No transactions recorded.

No transactions recorded.

No transactions recorded.

No transactions recorded.

No transactions recorded.

No transactions recorded.

No transactions recorded.

Inside Trans: OSR Holdings, Inc. (OSRH) by Hwang Kuk Hyoun (President and CEO) on 2025-02-14
- Common Stock: 43000 shares at $0 (I) Footnote: Represents 430,000 private placement rights which were converted into 43,000 shares of common stock at the closing of the business combination between Bellevue Life Science Acquisition Corp. and OSR Holdings Co., Ltd.
- Common Stock: 7531634 shares at $0 (I) Footnote: Represents shares of OSR Holdings, Inc. common stock acquired by BCM Europe AG in exchange for its shares of OSR Holdings Co., Ltd. common stock at the closing of the business combination between Bellevue Life Sciences Acquisition Corp. and OSR Holdings Co., Ltd.
- Common Stock: 3123970 shares at $0 (I) Footnote: Represents shares of OSR Holdings, Inc. common stock acquired by Bellevue Capital Management LLC in exchange for its shares of OSR Holdings Co., Ltd. common stock at the closing of the business combination between Bellevue Life Sciences Acquisition Corp. and OSR Holdings Co., Ltd.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.6
Average Volume: 160249.0
30-Day High: 3.66
30-Day Low: 1.3305
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

OSRH_OUT_23 [2025-03-26 07:54:19 -0400] 676 Bytes | 167 tokens | Cum: 4251 tkns (53.14% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

OSRH_IN_25 [2025-03-26 07:54:19 -0400] 126 Bytes | 29 tokens | Cum: 4308 tkns (53.85% of 8k)
==========================================================================

====================================
[2025-03-26 04:54:19] # Analysis Completed
Elapsed Time: 44.77 seconds